Lantheus acquired by Curium: fairness opinion
Announced July 27, 2026 · Merger ·
DEFM14A filed September 8, 2026
Enterprise value
$7.0B
EV / LTM EBITDA
14.1x
EBITDA $497M · 32% margin
EV / LTM revenue
4.54x
revenue $1.5B
DCF discount rate
8.8%–10.7%
Deal terms
Consideration—
Price per share—
Premium—
Premium basis—
StructureMerger
Termination fee—
Reverse termination fee—
Go-shopNone
Outside date—
FilingDEFM14A · EDGAR index
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
Management projections
| Projection year | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.8B | $2.0B | $2.0B | 7.5% |
| Revenue growth | -1.9% | 7.1% | 11.5% | 8.1% | 3.2% | |
| EBITDA | — | — | — | — | — | — |
| EBITDA growth | — | — | — | — | — | |
| EBITDA margin | — | — | — | — | — | |
| Implied EV / EBITDA | — | — | — | — | — |
Year-1 growth is against LTM at announcement ($1.5B revenue, $497M EBITDA); later years are year over year.
Other Diagnostics / Life Sciences fairness opinions
- BioLife Solutions / Repligen 2026 · 60.0x EV/EBITDA
- Personalis / Tempus 2026
- BIO-TECHNE / Merck 2026 · 26.2x EV/EBITDA
- Masimo / Danaher 2026 · 21.2x EV/EBITDA
- Exact Sciences / Abbott 2025 · 44.2x EV/EBITDA
- Enzo Biochem / Battery Ventures 2025